Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Laura Obici(University of Pavia), Conceição de Azevedo Coutinho, Inês Lopes Cardoso, Jonas Wixner(Umeå University), John L. Berk(Boston University), Karin Söderberg, Ulrika H. Englund, Helder Martins, Björn Pilebro(Umeå University), Filipa Lamas, Chongshu Chen(Alnylam Pharmaceuticals (United States)), Patrícia Rodrigues(Administração Regional de Saúde de Lisboa e Vale do Tejo), Intissar Anan(Umeå University), Javier Martínez Pérez(Hospital de Santo António), Erica Uneus, Cristina Alves(Centro Hospitalar do Porto), Emre Aldinc(Alnylam Pharmaceuticals (United States)), Julia R Monte(Centro Hospitalar do Porto), Ricardo Cotrin Teixeira, Anna Ekman, Kristin Samuelsson(Karolinska University Hospital), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Miguel Oliveira Santos(Centro Hospitalar Lisboa Norte), Haruki Koike(Shinshu University), Senda Ajroud‐Driss, Isabel Conceição(Université Paris-Sud), Natália Ferreira, Kon‐Ping Lin(Taipei Veterans General Hospital), Catarina Falcão de Campos, Parag Kale(Baylor University Medical Center), Márcio Cardoso(Centro Hospitalar Lisboa Norte), Carla Rodrigues, Marta Novais, Ana Silva(Alnylam Pharmaceuticals (United States)), Fredrik Edbom, Rolf Backlund, Mirjam Bilecen, Mónica G. Silva, David Adams(Mount Sinai Health System), Teresa Coelho(Universidade do Porto), Rayomand Press(Karolinska University Hospital), Antonio Hipólito Reis(The Royal Free Hospital), A Nilzén, Sandra Arvidsson, Joana Ramalho, Nádia Guimarães, David Danese(Alnylam Pharmaceuticals (United States))
Cited by 21
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k